Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.01.13	Teijin Pharma to Launch Ipsen's Somatuline® Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan (Businesswire)
07.01.13	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
07.01.13	Ipsen S.A. : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.01.13	Ipsen's Corporate Agenda for 2013 (Businesswire)
18.12.12	Oncodesign And the Laboratory for Neurobiology and Gene Therapy at The KU Leuven Enter into a Research Collaboration for Advancing Drug Discovery Efforts with Ipsen in Parkinson's Disease (Businesswire)
10.12.12	Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer (Businesswire)
06.12.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
03.12.12	Ipsen and Galderma increase their collaboration for Dysport® in new territories (Businesswire)
20.11.12	Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A (Businesswire)
09.11.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
31.10.12	Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection (Businesswire)
29.10.12	Ipsen’s third quarter and first nine months 2012 sales (Businesswire)
23.10.12	Ipsen US Awards up to $300,000 for Dystonia Fellowship Grants in 2013 (Businesswire)
19.10.12	Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications (Businesswire)
05.10.12	IPSEN SA: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.10.12	Ipsen initiates a phase II "Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod (Businesswire)
03.10.12	Ipsen Provides Update on Recent Agreement with Inspiration (Businesswire)
01.10.12	Tasquinimod Biomarker Phase II data presented at ESMO 2012 (Businesswire)
10.09.12	Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US (Businesswire)
07.09.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
28.08.12	Ipsen's Half-Year 2012 Results (Businesswire)
21.08.12	Ipsen and Inspiration Biopharmaceuticals Renegotiate Strategic Partnership Agreement (Businesswire)
02.08.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
11.07.12	Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope (Businesswire)
10.07.12	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
10.07.12	Ipsen’s Partner Inspiration Biopharmaceuticals Announces Hold of Phase III Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Hemophilia B (Businesswire)
06.07.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
29.06.12	Ipsen’s Somatuline® Receives Marketing Approval in Japan for the Treatment of Acromegaly and Pituitary Gigantism (Businesswire)
05.06.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
04.06.12	Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer (Businesswire)
01.06.12	Combined Shareholders’ Meeting of IPSEN S.A. Held on 1 June 2012 (Businesswire)
21.05.12	600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders’ Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders’ Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)
17.04.12	Ipsen’s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)
06.04.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.04.12	The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences Series: "Programmed Cells: from Basic Neuroscience to Therapy” (Businesswire)
02.04.12	The Ipsen Group publishes its 2011 Registration document (Businesswire)
05.03.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
29.02.12	Ipsen’s 2011 Results and 2012 Objectives (Businesswire)
24.02.12	Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress (Businesswire)
07.02.12	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
02.02.12	Ipsen’s fourth quarter and full year 2011 sales and other significant developments (Businesswire)
27.01.12	Ipsen Acknowledges Tanakan® Delisting in France (Businesswire)
24.01.12	Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement (Businesswire)
12.01.12	Half-Year IPSEN Liquidity Contract Statement Entered into With NATIXIS (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten